Mapracorat

Cat. No.: HY-14864

CAS No.: 887375-26-0

Molecular Formula: $C_{25}H_{26}F_4N_2O_2$

Molecular Weight: 462.48

Target: Glucocorticoid Receptor

Pathway: Immunology/Inflammation; Vitamin D Related/Nuclear Receptor

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 33.6 mg/mL (72.65 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	2.1623 mL	10.8113 mL	21.6226 mL
5 mM	0.4325 mL	2.1623 mL	4.3245 mL
10 mM	0.2162 mL	1.0811 mL	2.1623 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Mapracorat is a novel non-steroidal selective glucocorticoid receptor agonist.

In Vitro

Mapracorat concentration dependently inhibited TNFα secretion from activated canine PBMC with IC_{50} value of approximately 0.2 nM.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Intradermal injection of compound 48/80 (50 μg in 50 μL saline) resulted in a clear wheal and flare reaction over the 60 min observation period. Topical pre-treatment with mapracorat (0.1%) leads to significant reduction in the wheal and flare responses compared to vehicle (acetone) treated areas.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Patent. US20220047602A1.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Bäumer W , et al. The selective glucocorticoid receptor agonist mapracorat displays a favourable safety-efficacy ratio for the topical treatment of inflammatory skin diseases in dogs. Vet Dermatol. 2017 Feb; 28(1):46-e11.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA